Study	Threshold	TP	FP	FN	TN	Se [95% CI]	Sp [95% CI]
Liu 2023	4.6	23	162	17	264	0.58 [0.42, 0.71]	0.62 [0.57, 0.66]
Ciancio 2022	3.25	60	458	11	471	0.85 [0.74, 0.91]	0.51 [0.47, 0.54]
Zou 2022	3.25	17	256	10	418	0.63 [0.44, 0.78]	0.62 [0.58, 0.66]
Ideno 2022	3.25	67	252	10	361	0.87 [0.78, 0.93]	0.59 [0.55, 0.63]
Kumada 2022	3.25	21	217	30	1,116	0.41 [0.29,0.55]	0.84 [0.82, 0.86]
Ampuero 2022	3.25	44	504	12	494	0.79 [0.66, 0.87]	0.49 [0.46, 0.53]
Tahata 2021	3.25	41	561	11	860	0.79 [0.66, 0.88]	0.61 [0.58, 0.63]
Kumada 2021	1.5	53	852	2	445	0.96 [0.88, 0.99]	0.34 [0.32, 0.37]
Matsumae 2023	2.625	17	199	6	301	0.74 [0.54, 0.87]	0.60 [0.56, 0.64]
Myojin 2022	3.25	39	308	11	606	0.78 [0.65, 0.87]	0.66 [0.63, 0.69]
Ide 2019	4.6	59	915	4	547	0.94 [0.85, 0.98]	0.37 [0.35, 0.40]
Nagaoki 2020	5	20	122	9	147	0.69 [0.51, 0.83]	0.55 [0.49, 0.60]
Ioannou 2019	3.25	168	875	63	1145	0.73 [0.67, 0.78]	0.57 [0.55, 0.59]
	3.25	529	4,458	90	2,456	0.85 [0.82, 0.88]	0.36 [0.34, 0.37]
	3.25	168	1,762	203	14,718	0.45 [0.40, 0.50]	0.89 [0.89, 0.90]
	3.25	167	4,515	121	16,697	0.58 [0.52, 0.64]	0.79 [0.78, 0.79]
Kramer 2022	3.25	1,418	9,249	986	17,745	0.59 [0.57, 0.61]	0.66 [0.65, 0.66]
	1.45	561	29,138	282	33,188	0.67 [0.63, 0.70]	0.53 [0.53, 0.54]
Kim 2023	1.45	33	938	1	276	0.97 [0.85, 0.99]	0.23 [0.20, 0.25]
	1.5	33	914	1	300	0.97 [0.85, 0.99]	0.25 [0.22, 0.27]
	2.625	31	563	3	651	0.91 [0.77, 0.97]	0.54 [0.51, 0.56]
	3.25	29	415	5	799	0.85 [0.70, 0.94]	0.66 [0.63, 0.68]
	4.6	23	259	11	955	0.68 [0.51, 0.81]	0.79 [0.76, 0.81]
	5	20	235	14	979	0.59 [0.42, 0.74]	0.81 [0.78, 0.83]



A

Study	Threshold	TP	FP	FN	TN	Se [95% CI]	Sp [95% CI]
Liu 2023	3.7	24	124	16	302	0.60 [0.45, 0.74]	0.71 [0.66, 0.75]
Azzi 2022	3.25	74	478	79	2,900	0.48 [0.41, 0.56]	0.86 [0.85, 0.87]
Caviglia 2022	3.38	40	234	17	341	0.70 [0.57, 0.80]	0.59 [0.55, 0.63]
Tada 2022	3.25	72	829	35	2122	0.67 [0.58, 0.75]	0.72 [0.70, 0.74]
Kuo 2022	3.6	17	145	11	524	0.61 [0.42, 0.76]	0.78 [0.75, 0.81]
Hiraoka 2019	3.25	11	112	11	350	0.50 [0.31, 0.69]	0.76 [0.72, 0.79]
Ogawa 2020	3.25	11	124	5	150	0.69 [0.44, 0.86]	0.55 [0.49, 0.61]
Tamaki 2021	3.25	75	925	48	2,775	0.61 [0.52, 0.69]	0.75 [0.74, 0.76]
Kim 2023	3.25	19	220	15	994	0.56 [0.39, 0.71]	0.82 [0.80, 0.84]
	3.38	17	199	17	1,015	0.50 [0.34, 0.66]	0.84 [0.81, 0.86]
	3.6	17	170	17	1,044	0.50 [0.34, 0.66]	0.86 [0.84, 0.88]
	3.7	17	152	17	1,062	0.50 [0.34, 0.66]	0.87 [0.85, 0.89]



B

Supplementary Figure 4. Forest plots of studies included in the diagnostic accuracy analysis for the prediction of HCC using FIB-4 measured at (A) pre-treatment and (B) after SVR. HCC, hepatocellular carcinoma; FIB-4, fibrosis-4 index; SVR, sustained virological response.